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Dear Editor, 
 
Our manuscript  ‘Neoadjuvant Docetaxel-Based Chemoradiation for Resectable 
Adenocarcinoma of the Pancreas.’ was approved by all authors. This work was not 
submitted elsewhere and no authors have conflict of interests. 
 
Olivier Turrini, MD 
Department of Surgical Oncology 
 
 Purpose: to assess the safety and efficacy of a new neoadjuvant chemoradiation (CRT) 
docetaxel-based regimen in patients with resectable adenocarcinoma of the pancreatic head 
or body. 
Patients and Methods: 34 patients with histologically-confirmed resectable pancreatic 
adenocarcinoma were included in this prospective two-center phase II study. Radiotherapy 
was delivered at the dose of 45 Gy in 25 fractions of 1.8 Gy per fractions, 5 days/week, over 
5 weeks. Docetaxel was administered as a 1-hour intravenous (IV) infusion repeated every 
week during 5 weeks. The dose was 30 mg/m²/week.  All patients were restaged after 
completion of CRT.  
Results: Tumor progression was documented in 11 patients (32%), stable disease was 
documented in 20 patients (59%), and partial remission was documented in 3 patients (9%). 
23 patients still with local disease at restaging underwent explorative laparotomy. Of this, 17 
patients (50%) had a curative pancreaticoduodenectomy with lymphadenectomy. Morbidity 
and mortality rates were 29% and 0%, respectively. Three patients (17%) had complete 
histological responses and 5 patients had minimal residual disease. All resected patients 
(n=17) underwent R0 resection. The median and five-year survival times for the resected 
patients were 32 months and 41%, respectively. Among the resected patients, ten (59%) 
died as a result of recurrent pancreatic cancer without local tumor bed recurrence.  
Conclusions: Neoadjuvant docetaxel-based chemoradiation is well tolerated. Resected 
patients had a prolonged survival time. Further studies are needed to confirm our findings 
and determine the role of such a neoadjuvant approach. 
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Introduction 
Surgery remains the gold standard for the treatment of pancreatic carcinoma. Nevertheless, 
the long-term prognosis of patients with resectable cancer of the pancreatic head remains 
dismal, with a median overall survival of approximately 12 months after 
pancreaticoduodenectomy (PD) alone1. Tumor size, lymph node metastasis and resection 
margins2 are the main factors affecting survival rate. Better patient selection and 
multimodality treatment concepts are crucial to improving survival. Although the addition of 
radiotherapy to adjuvant chemotherapy remains controversial, adjuvant chemotherapy alone 
has demonstrated a benefit in recurrence-free and overall survival times3,4. However, at least 
25% of the patients at risk do not receive adjuvant treatment after PD for various reasons5. 
This major shortcoming can be prevented by the use of a neoadjuvant regimen6,7. 
Preoperative regimens for patients with resectable pancreatic cancer have only been 
investigated in a few studies and were based on chemoradiotherapy (CRT) in which the final 
resectability rates ranged between 30% and 75%8-17 (table 1). 
The aim of the current study was to assess the safety and efficiency of a new neoadjuvant 
CRT docetaxel-based regimen in patients with resectable pancreatic head adenocarcinoma. 
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Patients and Methods  
Eligibility criteria 
Between May 2003 and July 2005, 34 patients with histologically-confirmed pancreatic 
adenocarcinoma were included in this prospective phase II study. All patients were treated 
either at the Institut Paoli-Calmettes (Marseille, France) or at the Centre Val d’Aurelle 
(Montpellier, France). Patients having any major comorbidity precluding consideration of 
pancreatic surgery were excluded. Patients with tumor surrounding >180° of the 
circumference of the portal or superior mesenteric vein, or occlusion of the superior 
mesenteric vein (SMV) or portal vein (PV) confluence, or direct tumor extension to either the 
superior mesenteric artery (SMA) or the celiac axis, or with evidence of extrahepatic disease 
were considered non-resectable. Patients with adenocarcinoma of the tail of the pancreas, 
intraductal papillary-mucinous adenocarcinoma, tumors of neuroendocrine origin or patients 
with carcinoma of the duodenum, distal common bile duct, or Ampulla of Vater were also 
excluded. Patients were also required to have a Karnofsky performance status of at least 70 
and a serum bilirubin level less than 10 mg/dL. Patients diagnosed with jaundice underwent 
primary biliary decompression. Patients with resectable disease associated with high serum 
CA19-9 level (>200 UI/mL) after biliary decompression were not excluded for neoadjuvant 
treatment or surgery as radiological staging did not detect distant metastasis. The protocol 
was approved by the Ethics Committee (Comité Consultatif de Protection des Personnes 
dans la Recherche Biomédicale, CCPPRB) of both centers and all patients were included 
after informed consent.  
Disease staging 
Disease was affirmed and staged by physical examination, biopsy (fine needle aspiration 
with Wilson-Cook 22 gauge, 8 cm needles) obtained by endoscopy under ultrasound 
guidance (EUS) (Pentax-Hitachi, Hamburg, Germany) and thin-section contrast-enhanced 
helical dual phase scanning (CT scan). We used semiautomatic bolus-tracking programs 
provided by the manufacturers to determine the starting time for arterial phase scanning. A 
region of interest was drawn on the aorta at the level of the diaphragm, and the trigger level 
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was set at 90 HU. Arterial phase scanning was started 11 seconds after the aortic 
enhancement reached the trigger level. Scanning began at the diaphragm and continued 
caudally to the inferior margin of the liver during a single breath hold. Hepatic arterial phase 
scanning delays were 11–17 seconds after descending aorta enhancement to 100 HU, as 
measured with use of a bolus-tracking technique, and portal venous phase interscanning 
delays were 20–30 seconds after the aortic enhancement. Equilibrium phase images were 
acquired 180 seconds. 
All patients were restaged after completion of CRT. Surgery was scheduled at 4–6 weeks 
after the end of neoadjuvant CRT. The laparoscopic approach was not routinely used. 
Treatment plan  
Radiotherapy was delivered at the dose of 45 Gy in 25 fractions of 1.8 Gy per fractions, five 
days/week, over five weeks. A CT-scan was done on all patients in order to perform a three-
dimensional CT-based treatment plan. The clinical target volume (CTV) was defined by the 
tumor and the regional lymph nodes with a 2-cm margin. Planning target volume (PTV) was 
defined by CTV with a 1-cm margin. A 4-field technique was used with >6 MV photons. A 
cumulative dose-volume histogram was recommended: the dose to the spinal cord was 
limited to 35 Gy and no more than 30% of the total kidney volume received >50% of the 
prescribed dose. 
Docetaxel was administered as a 1-hour intravenous (IV) infusion repeated every for 5 
weeks. The dose was 30 mg/m²/week. A preliminary Phase I study had established the exact 
amount of docetaxel to be administered in combination with radiotherapy localized to the 
pancreas18. All patients received dexamethasone 8 mg orally at 12, 7 and 1 hour(s) before 
docetaxel and again at 12 hours following docetaxel administration. Complete blood cell 
counts were measured weekly. If the leukocyte count was > 2 x 109/l and platelets > 100 x 
109/l, a full dose of docetaxel was administered.  
 
Week 1 Week 2 Week 3 Week 4 Week 5 
 
EBRT, 45 Gy, 25 fractions 
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D  D  D  D  D 
 
                                             
(D: DOCETAXEL 30 mg/m²/week; EBRT: External-Beam Radiation Therapy) 
 
World Health Organization (WHO) Grade 2, 3 or 4 toxicity events were recorded during CRT. 
Surgery 
Surgery was performed through a bisubcostal incision. Exploration was done to identify the 
presence of liver metastases or carcinomatosis. Assessment of local invasion was begun by 
dissection of the SMA and eventual biopsy of vessel walls. Patients with tumor located in the 
pancreatic body (n=15) underwent PD; no patients had mid-gland resection to avoid positive 
right pancreatic margins and ensure optimal clearance of retropancreatic soft tissues. PD 
was associated with superior mesenteric artery lymphadenectomy to obtain optimal 
retropancreatic clearance. Extended lymphadenectomy included dissection of the PV, 
peripancreatic and paraduodenal nodes, dissection of the uncinate process, and complete 
removal of the aortocaval nodes behind the pancreas. The lymph node dissection included 
the celiac axis nodes, those along the hepatic artery with dissection of the root of the right 
gastric artery, and a SMA lymphadenectomy. A Child procedure was routinely performed. 
Radiological Tumor Response 
Radiological tumor response was determined using Response Evaluation Criteria in Solid 
Tumors (RECIST) criteria for staging and restaging on CT scans.  
Histological analysis 
Specimens were routinely stained to assess various resection margins: portal vein bed, 
pancreatic section and retroportal bed. Margin positivity was defined by the presence of 
tumor at or <=1 mm of a margin when assessed by microscopy.  Tumor size, number and 
status of lymph nodes, and resection margins were noted. Staging was done according to 
the TNM classification of the American Joint Committee on Cancer. The absence of residual 
cancer in the resected specimen after RCT was defined as a complete pathologic response 
(Stage 0) and a partial histological response with minimal residual disease (> 50% tumor 
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destruction). The tumor was Stage I or IIA (ypT1 or ypT2, N0, M0) if it was localized and 
involved only the pancreas, bile duct and/or duodenum. If the tumor invaded regional lymph 
nodes, it was Stage IIB ( ypT1-3, N1, M0). A tumor was Stage III if neoplastic disease was 
growing outside the pancreas into nearby large blood vessels or major nerves with or without 
involving lymph nodes (ypT4, N0-1, M0). Metastases extending beyond regional lymph 
nodes defined Stage IV disease (any T, any N, and M1). 
 
Study Endpoints, Data Collection and Statistical Analysis 
The study end point was the resectability rate (>60%) based on the restaging procedures. If 
a tumor was found to be unresectable only on surgical exploration, nonresectability was not 
attributed to neoadjuvant chemoradiation because resectability was presumably also 
misdiagnosed by the initial staging. On the basis of this assumption a total of 34 patients 
were required according to Simon’s two-stage phase II design to achieve a power of 80% 
(p<0.05). The risk of rejecting an effective treatment or of accepting an ineffective treatment 
is 10% each. 
Mortality was calculated for the post-operative period covering 30 days after surgery or until 
hospital discharge. All living patients were evaluated by combined medical and surgical 
teams at one, four and six months postoperatively and every six months thereafter. Staging 
always involved physical examination, thin-section contrast- enhanced helical dual phase CT 
scan and tumor markers (CEA, CA 19-9). The type of recurrence was also noted 
(metastasis/carcinomatosis, local recurrence). 
Survival was measured from the date of diagnosis to the date of death or January 1, 2009, 
the censor date. Survival was examined using the Kaplan-Meier method. Statistical 
comparisons were conducted using the log rank and Wilcoxon methods.  
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Results 
The median time between diagnosis and the beginning of chemoradiation was 35 days 
(range 15- 68). The median time between diagnosis and surgery was 3.5 months (range 2.9- 
8.7). Patient characteristics are summarized in table 2. 
Treatment outcome and resectability  
Neoadjuvant CRT was delivered on an outpatient basis in all 34 patients. Thirty-one patients 
(91%) received the complete CRT regimen.  A total 23 of 34 patients (68%) were found to 
have resectable disease upon restaging. Thus, 11 patients had disease progression and did 
not  undergo surgery: 9 patients developed distant metastasis and 2 patients had local 
progression of the tumor with vascular involvement precluding surgery. During explorative 
laparotomy (n=23), 17 were found to have resectable disease and underwent PD (50%). 
Reasons for non-resection were carcinomatosis in three patients, liver metastases in two 
patients, and involvement of the SMA in one patient. PV resection was needed in five 
patients due to macroscopic suspicion of invasion, microscopically confirmed in one patient. 
Morbidity and mortality rates were 29% and 0%, respectively. One patient experienced a 
pancreatic fistula grade A. No patients developed postoperative hemorrhage. 
Toxicity 
Adverse effects during CRT are summarized in table 3. No patients experienced grade 4 
toxicity. 
Radiological tumor response 
Twenty-seven patients were submitted to echo-endoscopy to determine the post-CRT/pre-
surgery diameter of the tumor. The diameter remained unchanged before (median: 3 cm, 
range 2-6.5) and after (median: 3 cm, range 0-6.5) CRT. According to the RECIST evaluation 
of tumor response, tumor progression was documented in 11 patients (32%), stable disease 
was documented in 20 patients (59%), and partial remission was documented in three 
patients (9%). 
Pathological findings 
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Three patients (17%) had complete histological responses (stage 0) and five patients had 
minimal residual disease. Tumor fibrosis was present in all specimens. Regional lymph 
nodes were involved in four patients (24%). All resected patients (n=17) underwent R0 
resection. 
Disease Recurrence 
Among the resected patients, ten (59%) died as a result of recurrent pancreatic cancer 
without local tumor bed recurrence. The liver was the most common site of tumor recurrence 
(7 of 10 patients, or 70%). Carcinomatosis occurred in two patients (20%) and lung 
metastasis in one patient (10%).  
Survival (figure 1) 
No patients were lost to follow-up through the censor date of January 1, 2009. Median time 
of follow-up was 54 months (range 38-65). The median overall survival for all patients (n=34) 
was 15.5 months (95% CI [12.1-31.9]); the five-year survival for all 34 patients was 20.6% 
(95% CI [10.6-39.8]).  
Median survival for resected (n=17) vs. unresected (n=17) patients was 32 months (95% CI 
[22.3-37.2]) and 11 months (95% CI [7.3-14.7]), respectively (p<0.001). The five-year 
survival for resected vs. unresected patients was 41% and 0% (p<0.001), respectively. The 
overall progression-free survival for resected patients was 23 months (95% CI [21.5-24.5]).  
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Discussion 
Cancer of the pancreatic head is considered locally resectable when infiltration of 
surrounding organs and arteries is absent. After curative resection, adjuvant chemotherapy 
improves survival3,4 but at least 25% of patients cannot receive this treatment because of 
complications related to surgery5.Thus, several teams have supported the use of 
preoperative (neoadjuvant) treatment8-17 offering several theoretical advantages such as a 
multimodal treatment concept for all patients, a potentially higher R0 resection rate, and the 
treatment of micrometastases before surgery when using neoadjuvant chemotherapy. 
Moreover, in our study, we noticed that 14 patients (41%) developed distant metastases 
during CRT, at restaging or during explorative laparotomy. Thus, resection could be avoided 
and, as published by several teams16, neoadjuvant treatment should combine chemotherapy 
followed by CRT in patients without distant metastasis detected at restaging after completion 
of chemotherapy. On the other hand, this concept harbors the risk of disease progression 
during therapy because of the aggressiveness of the tumor or due to ineffective treatment. 
Indeed, 3 patients (9%) who had resectable disease at diagnosis had local tumor 
progression during CRT and subsequently did not have curative PD. 
After having initially tested the docetaxel/radiotherapy combination in a phase I study18, we 
are now presenting our results for the neoadjuvant approach. A total 91% of patients were 
able to receive complete pre-operative treatment, even with the elevated intensity dose of 
docetaxel (30 mg/m²/week, a dose within the range of the DMT gained from docetaxel used 
alone). Gemcitabine studies have also reported good feasibility (>80% of patients receive the 
entire treatment) but with a reduced intensity dose19. Our strategy of a minimal radiotherapy 
(45 GY over a 5-week period instead of 50.4 GY) was based on the presumed toxicity of our 
chemotherapy regimen. However, we remarked the feasibility of a low toxicity 
docetaxel/radiotherapy treatment when used in a neoadjuvant setting for the treatment of 
locally resectable pancreatic adenocarcinoma. 
The resectability rate on restaging examinations was 68% and the definitive resectability rate 
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after explorative laparotomy was 50%. This rate was lower than the resectability rate already 
published in patients receiving neoadjuvant chemoradiation (table 1).  We did not use high 
CA19-9 serum levels to exclude patients for surgery. However, it is now accepted that a 
CA19-9 rate above 200-400 U/ml is a poor prognostic factor even for patients presenting with 
resectable pancreatic carcinoma without distant metastasis detected at preoperative 
staging20. Moreover, Maithel et al. recently reported a benefit matching CA19-9 serum level 
(over 130 U/mL) and a laparoscopic approach to avoid unnecessary laparotomy21. In 
hindsight, using both CA19-9 serum levels and laparoscopic staging might have decreased 
our disease progression rate during neoadjuvant treatment and improved our resection rate, 
thus optimizing patient selection for our study.  Furthermore, we now speculate that patients 
with high serum CA19-9 levels may benefit from a neoadjuvant sequence of chemotherapy 
(gemcitabine) followed by CRT. After completion of chemotherapy, and prior to CRT, patients 
could be restaged and those with metastases could avoid subsequent radiation and surgical 
insults16. Our study included patients with adenocarcinoma of the pancreatic body (n=15) that 
likely involved nearby vascular structures (SMA, celiac axis, PV). Thus, these patients have a 
reduced probability of resection and we supposed that including only patients with cephalic 
head adenocarcinoma would increase our resectability rate. 
Surgery without preoperative treatment leads to more than 70% positive resection margins22. 
The local control provided by neoadjuvant CRT is difficult to ignore: findings of complete 
pathologic response, a low incidence of metastatic lymph nodes, a low incidence of margin 
positivity and absence of local recurrences when compared with patients who did not 
undergo neoadjuvant treatment9,23-26 are compelling arguments for the local impact of 
chemoradiation8-10,13,14,17,27-29, These findings are consistent with those noted in other series 
using neoadjuvant CRT.  
Despite the fact that the small number of patients included in our series precludes emphatic 
conclusions, we noticed an improved survival rate in patients undergoing the planned 
treatment (neoadjuvant CRT and PD). Indeed, the median survival time was 31.9 months 
and five-year survival estimate was 41%. Recent series reporting the use of neoadjuvant 
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chemotherapy followed by chemoradiation showed similar survival rates16. However, we 
believe that further studies on docetaxel-combined chemoradiation are needed to confirm our 
findings. Moreover, toxicity was acceptable and we hypothesize that neoadjuvant 
chemotherapy followed by docetaxel-based CRT should improve our actual results. 
 
Conclusions 
Neoadjuvant docetaxel-based chemoradiation for resectable pancreatic adenocarcinoma 
was safe, well-tolerated and showed improved survival rates. Screening patients with high 
serum CA19-9 levels with staging laparoscopy and employing “screening” systemic 
chemotherapy prior to neoadjuvant CRT might improve patient survival and selection of 
patients who may most benefit from such an approach. Pancreatic cancer treatment clearly 
needs more effective therapies, but also needs to balance treatment decisions with proper 
attention to patients’ quality of life.  Patients with micrometastases who will likely not benefit 
from local control treatments such as surgery or radiation should be optimally excluded from 
surgical and radiation-based treatment approaches.   
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 Table 1: Resection rate and survival of series with 5-Fu based neoadjuvant CRT. 
 year n Resection rate Median survival, all patients 
(months) 
Median survival, resected 
patients (months) 
Evans et al.8 1992 28 17/28 (61%) - - 
Spitz et al.9 1997 91 41/91(45%) - 19.2 
Hoffman et al.10 1998 53 24/53 (45%) 9.7 15.7 
Snady et al.11 2000 68 20/68 (30%) 23.6  32.3  
Breslin et al.12 2001 132 - - 21  
White et al.13 2001 68 20/68 (30%) - Non reached at 16 months 
Mehta et al.14 2001 15 9/15 (60%) -  30  
*Evans et al.15 2008 86 64/86 (74%) 22.7 34 
*Varadhachary et 
al.16 
2008 90 52/79 (66%) 17.4 31 
Turrini et al.17 2008 102 62/101 (61%) 17 23 
Current series 2009 34 17/34 (50%) 15.5 31.9 
*gemcitabine-based neoadjuvant CRT or preoperative chemotherapy followed by gemcitabine-based CRT 
 
 Table 2: Baseline Patient Characteristics 
 
Characteristics  
Mean age 61.5 range [40-72] 
Gender 
Male 
Female 
 
21 
13 
Tumor localization 
Head 
Body 
 
18 
15 
Median tumor size (cm) 2.95 range [1.4-6.5] 
Pretreatment US staging 
T1 
T2 
T3 
 
7 
25 
2 
Median pretreatment CA19.9 (UI/ml) 114 range [1-9432] 
ECOG status 
0 
1 
2 
 
21 
12 
1 
 
 
 Table 3: toxic events during RCT according to WHO classification.  
 
 grade 2 grade 3 grade 4 grade 5 Total 
Digestive  
  Biliary sepsis 
  Nausea / vomiting 
  Diarrhea 
   
10 
2 
4 
4 
2 
- 
2 
- 
 
- 
- 
- 
- 
- 
- 
- 
- 
12 (35%) 
Weight loss 11  - - - 11 (32%) 
Fever 5  - - - 5 (15%) 
Hematologic  6  - - - 6 (18%) 
Skin 1  - - - 1 (3%) 
Patients 11 (32%) 2 (6%) 0 0 13 (38%) 
 
 
 
 
 
 Figure 1: Overall Survival on intention-to-treat analysis (n=34) and of patients after 
pancraticoduodenectomy (n=17) patients 
 
 
 
Subjects at risk 
 
Months 0 12 24 36 48 60 
All   34 22 14 10 5 2 
Resected  17 16 11 8 5 2 
